Exelixis heads into its July 28 earnings with a notably more defensive options skew than at any point in recent months — even as short sellers add modestly to positions and the stock trades near analyst targets.
The options market is the clearest signal this week. The put/call ratio has climbed to 0.67, more than two standard deviations above its 20-day average of 0.55 — a defensive lean that stands out against a backdrop where the PCR has rarely moved this far from its norm. This is not a panic read; the 52-week high on the PCR is 1.81, so there is plenty of room to the upside. But the directional shift over the past two weeks is notable. The PCR was running near 0.50 through late May and early June, and has ratcheted higher in each of the past five sessions. Traders are paying more for downside protection heading into the next catalyst.
Short interest tells a more measured story, though the trend is worth watching. Bears hold roughly 11.6% of the free float — a genuinely elevated level — and that figure has grown about 1.3% over the past week and 3.4% over the past month. The pace is gradual, not aggressive. The lending market remains far from stressed: availability runs at 607%, meaning there are many more shares available to borrow than are currently lent out. Borrowing costs have risen sharply in percentage terms — up 25% on the week to 0.56% — but from such a low base that the absolute level barely registers as restrictive. The ORTEX short score of 67.4 has eased back slightly from a week-ago reading near 68.5, suggesting the short-side pressure is steady rather than accelerating.
The Street's posture is mixed in a revealing way. The consensus sits at $49.31 mean target against a $51.34 close — the stock is trading modestly above where analysts collectively think it belongs. The most recent action came today, with Citizens raising its target to $55 while maintaining Market Outperform. Earlier May moves were broadly constructive: TD Cowen, HC Wainwright, Morgan Stanley, Stifel, and Wells Fargo all raised targets after Q1 results, though most retained Hold or Neutral-equivalent ratings rather than upgrading conviction. The bull case rests on cabozantinib's durable revenue base, a $1.43 billion cash pile, and a $750 million buyback program. Bears point to asset impairments in 2026 and the question of whether near-term pipeline catalysts can sustain EPS growth once the buyback effect fades. At a PE near 13.7x and EV/EBITDA near 10x, the valuation is not stretched for a profitable biotech — but forward EPS growth estimates rank only in the 30th percentile, a brake on any premium re-rating.
Insider activity adds context without offering a clean read. The 90-day net is a net sell of roughly $22.9 million across multiple executives, including the CEO selling 128,497 shares at $51.10 on May 15 and the CFO selling 34,901 shares at $50.00 on May 18. The trades are clustered near the current price and carry low significance scores, suggesting routine plan sales rather than a directional signal. BlackRock recently added 614,603 shares and now holds 12.3% of the company — the largest institutional position — while D.E. Shaw added 1.74 million shares in the most recent quarter. The offsetting picture is that Invesco trimmed 1.56 million shares over the same period.
The prior earnings print from May 5 produced a 10.3% one-day gain and nearly 12% over the following five days — a powerful reaction that likely explains both the elevated short interest (shorts who got hurt rebuilding) and the growing put activity now (longs hedging a repeat or a reversal). The July 28 report is the next inflection point, and the widening gap between the options market's defensive lean and the relatively loose borrow conditions is the setup worth tracking into that date.
See the live data behind this article on ORTEX.
Open EXEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
